BEIJING (AP) — The pharmaceutical giant Bayer AG has become the latest foreign drug maker to come under scrutiny for its practices in China.

The German-based company said in a statement Friday that it is cooperating with Chinese authorities in the investigation of a potential case of unfair competition after officials visited a Bayer branch office in late August. Bayer did not provide further details of the case or say where the branch office was.

A wave of investigations has rattled foreign drug manufacturers in China. Authorities are probing whether British-based GlaxoSmithKline PLC and French rival Sanofi SA paid doctors to encourage the use of their medications.

Chinese media reports also say U.S.-based Eli Lilly and Co. spent millions of dollars on payments to Chinese doctors to prescribe its insulin products.

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.